-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NKKTO/CkrPOwWDksMzVMUEUrDikFrApglQZ9bL+h4PiKZFugnv0oKbuspE7KT4wk
 tLilTH8dHduQx2/YtlLoJw==

<SEC-DOCUMENT>0000950123-09-034799.txt : 20090814
<SEC-HEADER>0000950123-09-034799.hdr.sgml : 20090814
<ACCEPTANCE-DATETIME>20090813173821
ACCESSION NUMBER:		0000950123-09-034799
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090813
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090814
DATE AS OF CHANGE:		20090813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		091011544

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c89347e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): August 13, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>ONCOGENEX PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>033-80623</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>95-4343413</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1522 217th Place S.E.<BR>Bothell, Washington<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>98021</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(425) 686-1500</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>N/A<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Item</B>&nbsp;<B>7.01 Regulation&nbsp;FD Disclosure.</B>
<BR>
&nbsp;
<BR>
On August&nbsp;13, 2009, OncoGenex Pharmaceuticals, Inc. issued a press release entitled &#147;OncoGenex Expands Clinical
Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer.&#148; A copy of the press release is attached as
Exhibit&nbsp;99.1 and incorporated herein by reference.
<BR>
&nbsp;
<BR>
In accordance with General Instruction B.2 of Form&nbsp;8-K, the information in this report, including the exhibit attached
hereto, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), nor shall such information be deemed incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a
filing.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P align="left" style="font-size: 10pt; text-indent: 2%">(d)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of OncoGenex Pharmaceuticals, Inc. dated August&nbsp;13, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;



<P align="center" style="font-size: 10pt">&nbsp;







<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ONCOGENEX PHARMACEUTICALS, INC.</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: August&nbsp;13, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Stephen Anderson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">Stephen Anderson<BR>
Chief Financial Officer and Secretary</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B><BR>
&nbsp;


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of OncoGenex Pharmaceuticals, Inc. dated August&nbsp;13, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c89347exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="right" style="font-size: 10pt"><B>Exhibit 99.1</B>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt"><IMG src="c89347c8934701.gif" alt="(LOGO)">
</DIV>

<P align="center" style="font-size: 10pt"><B>OncoGenex Expands Clinical Development of OGX-427<BR>
with a Phase 1 Clinical Trial in Bladder Cancer</B>



<P align="left" style="font-size: 10pt"><B>BOTHELL, WA, and VANCOUVER &#151; August&nbsp;13, 2009 &#151; </B>OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the
first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when
administered directly into the bladder in patients with bladder cancer. This trial is separate from an ongoing Phase 1
trial of OGX-427 administered systemically in patients with various solid tumors. OGX-427 is a second-generation
antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that
inhibits apoptotic cell death through multiple pathways.


<P align="left" style="font-size: 10pt">The study, which will enroll up to 36 patients with bladder cancer, is designed to determine the safety and potential
benefit of OGX-427 administered directly into the bladder using a catheter, which is called intravesical instillation.
In addition, the study will measure the direct effect of OGX-427 on expression of Hsp27 in bladder tumor cells as well
as determine the pharmacokinetics and pharmacodynamics of OGX-427 when delivered by intravesical instillation. The
study is sponsored by the National Cancer Institute of Canada (NCIC). Dr.&nbsp;Alan So, an Assistant Professor in the
Department of Urologic Sciences at the University of British Columbia and Research Scientist at the Vancouver Prostate
Centre, is the study&#146;s principal investigator.


<P align="left" style="font-size: 10pt">&#147;The current treatment for superficial bladder cancer is local resection with immunotherapy, which often has
significant local and systemic side effects,&#148; said Dr.&nbsp;So. &#147;Because of the limitations of current adjuvant options, a
treatment option like intravesical delivery of OGX-427 that is specifically targeted to the tumor would be desirable.&#148;


<P align="left" style="font-size: 10pt">&#147;This Phase 1 trial of OGX-427 is an attractive trial design as removal of bladder tumor samples after treatment allows
us to demonstrate inhibition of Hsp27 expression at the cellular level in the tumor,&#148; said Scott Cormack, President and
Chief Executive Officer of OncoGenex.


<P align="left" style="font-size: 10pt">&#147;By conducting this trial through an investigator-sponsored trial with leading clinical researchers at the Vancouver
Prostate Centre allows us to advance the development of OGX-427 without a significant commitment of our financial
resources,&#148; Cormack added.


<P align="left" style="font-size: 10pt">In preclinical studies conducted by the Vancouver Prostate Centre, OGX-427 had single-agent activity in multiple
cancers. In preclinical models of bladder cancer, the investigators observed that bladder cancer tumors were
significantly smaller six weeks after OGX-427 administration compared to the control group.


<P align="left" style="font-size: 10pt"><B>About OGX-427</B>


<P align="left" style="font-size: 10pt">OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer
treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to
inhibit cell death in tumor cells through a variety of mechanisms.


<P align="left" style="font-size: 10pt">OGX-427 is being evaluated in another Phase 1 clinical trial for the systemic (intravenous)&nbsp;treatment of solid tumors
including prostate, non-small cell lung, breast, ovarian, and bladder cancers. OncoGenex Pharmaceuticals, Inc. recently
announced preliminary results of this Phase 1 trial presented during an oral presentation at the 2009 American Society
of Clinical Oncology (ASCO)&nbsp;Annual Meeting. Results as of May&nbsp;2009 showed that OGX-427 was well tolerated as a
monotherapy. In addition, after treatment with OGX-427 patients experienced declines in circulating tumor cells at all
doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor
markers both suggest single-agent activity warranting further clinical investigation.


<P align="left" style="font-size: 10pt">Similar to OGX-011, OGX-427 has potential as a treatment in a broad number of cancers.


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="left" style="font-size: 10pt"><B>About OncoGenex</B>


<P align="left" style="font-size: 10pt">OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that
address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate
having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the
lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to
inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical
development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical
development.


<P align="left" style="font-size: 10pt">OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals
(NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis
partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial
development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to
OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial
obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions
regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the
University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.


<P align="left" style="font-size: 10pt">More information about OncoGenex is available at <U>www.oncogenex.com</U>.


<P align="left" style="font-size: 10pt">Forward Looking Statements


<P align="left" style="font-size: 10pt">This press release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the
Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the potential
activity and clinical benefit of OGX-427 and the anticipated clinical development activities and timing of these
activities. Such forward-looking statements are subject to risks and uncertainties, including, among others: the risk
factors set forth in the Company&#146;s filings with the Securities and Exchange Commission, including the Company&#146;s Annual
Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements
contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required
by applicable law.


<P align="center" style="font-size: 10pt">###



<P align="left" style="font-size: 10pt"><B>OncoGenex Contact:</B>
<BR>
Scott Cormack
<BR>
President &#038; CEO
<BR>
(604)&nbsp;736-3678
<BR>
scormack@oncogenex.com


<P align="left" style="font-size: 10pt"><B>Media and Investor Contact:</B>
<BR>
Jason Spark
<BR>
Porter Novelli Life Sciences
<BR>
(619)&nbsp;849-6005
<BR>
jspark@pnlifesciences.com


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c89347c8934701.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c89347c8934701.gif
M1TE&.#EAP0!)`'```"'Y!`$``/\`+`````#!`$D`A____X0``(2$A',``(P9
M$.;FSK6EK>;%Q>_O[^:EE+5SK;6EC+5K4K5K:XQ:4HQ:SCI:C&-:SA!:C-ZM
MK>9[C+U[A+5*8^;O6HR<E.;OE+6E:[WOQ>9[K;7O6K7OE+49:Q`I6A!:*>;.
M6N;.E+6E2K7.6K7.E+492A`(6A!:"!!*6HP9,:U*2HSO6CKOWCKO6HRE6CJM
MWCJM6HSOG(SO&3JMG#JM&8RE&3KOG#KO&8QC&8P9[SH9K8PIE#HIWF/OWF/O
M6A"MWA"M6F/OG&/O&1"MG!"M&6,9[Q`9K6.E6A#OWA#O6F.E&1#OG!#O&6,I
ME!`IWFMC&4((&3K.WCK.6HR$&3K.G#K.&8P(E#H(WA#.WA#.6F.$&1#.G!#.
M&6,(E!`(WF.$E$)C6K5"*>;6YHPZ4FL0.FL08^:ESN:E[^:E:^9"[^9":^:E
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M*1",K1",*6,ISA`IC&M"*8R$[V.$[XR$Q6.$Q8S.SHS.2CJ,SCJ,2HS.C(S.
M"#J,C#J,"(P(SCH(C&/.SF/.2A",SA",2F/.C&/."!",C!","&,(SA`(C&M"
M"!`I*>;O*;7O*1`(*>;.*;7.*1`I".;O"+7O"!`(".;."+7."&.$:X0`"(2$
M:SHI*8SO[XPZ$&.$2HR$2D(I"(SOSHR$E&-C2O__[P````C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G"CP'\6+&#-JW,BQ(T&+'D.*'$FR)$*0)E.J7,E2(<J6
M,&/*[/ARILV;.%WFW,ES9\V>0(.:_"FTJ%&-1(\J7>HP*=.G4#]&G4IUH-.J
M6(->37B@0AD"*RJ0$4KF@%D$2\GX\QF13(,!`P@TF#MF@4VT!"<T"`!WP(H)
M`O$"G4#@`%N&>`D/""!V8%?`.`^4@2NKP1BX`2"O1&"8X8)Y`SKCW$KP``&^
M#=86/(!6,,P#*^)JKL"7`%[7(R?(&JOPP#R^FF^2%D@F=H`Q>/WIK5!@)MX#
ML0:,X3UP;P#1*2<W3SAA<8#KAQE:_P\ML,"*Z`/F-;@;FP#U@63X5F!I@3Q"
MT]\#K'AO<WB!_"P(=``+%;CB%FJ!P<3`8@D<Y,]WP97D3P4#1`@`6K`MQL@`
M`8:GD'4!V`5`!=B]56%,\>F'FT"N$&#?BB%U)V)!",B2'W`\D5;<=RNXX@H`
M/Q+4X@"RQ$0;8PC%1T!+9`PP7T&NL.!=`+)8V!]#!P!8D&H"L?`==BFY8F,`
MVPVD&H5/KO0@"T$.9,&-%K3I(4)'(IG0D6FJU%T`!,CI&)$&P:@17K(L2=`"
M-^:9(T->0M@;7QTF^)"@=W[7IZ0`F.;>0)1Z1"%UON77H%!;(;!"?CX"L):?
M65+94J-L%O]402PK@-E0IX$:E,"+IWXW*JD+(<"(I?QM>=H*94XJD3^]1DK&
M`K&QP%M9"%&*ZY;P#<"`0&]^IRA0I>;'B)\T_E;89OF-84`%4A*IF6D#)&N2
M*RL4B:BW2FW5HJ6=[@L>D+A12@89UP[D+X`+!$?8=R(*AL"*`0=K$`N%G3K`
M>OD&F]^E"2'PVSR&3;""B!G*TIE@T%K:`%I!(C!!&2NPL$"0*09@`1GD(NJ=
MPC824`%>;NTF$&URM9;@@;%,AS*?W\6:\4+#!C"/PP;MZ]X!<,U'1F5O;5H=
M:@L2B5<!DQ%`\0!E'."/OY$>ZG,"^`))H0,5@#:?/Y.!!VT%LES_O)HL*S30
M]WX&_\:GK<`J9.IWC'1*QFEU(+!@B`"PL!Z]3@ZTP&(6C.C=6,7%U5SH/2*0
M+I<"3<""8:8.,"J%';ZUPMH\NI)E<YMONE8!<#4'KV;[SF-EX@IU:]]]D`)@
MW01DQ()A\JKV:EB6B_VXE^L#38!@U+85A/-`4LZ']0"\'?GC:;8QT+GR.';)
M(8NQS:B]S5"1=J^="-V['H69-;`M`/?JT/QFESH2`>D[LF@3L_BT(ZF1BR#A
M`\"".#9!()W&9.>BEZ,RE34!\654#>S14TC3*OJACB#=`@R>"`"9(Q7)<P%H
MFV.@!SX(U0EQ`^G;?&PTCQ_!"V.@&8-7_P8RK!.-*&Y2\MJ]7/2_I0QG#+7C
M%$$>QZ>A+68%TQG:=_YGG6]EZCOK^]IUL!8W5:W&;E;[(H=8ACZY!"8_+5Q,
M!?S1+L@,J0+:.]Y1AC,_RJT(;GZ;T``V%*GK/>E(&),57`+$)2]5R!]UB"*0
MS*A%QFC09G!I`'4,]R]_=>9(8QB<:(Z$,_05BT:8@LEP`%"&[]3AA``('<?J
M-!N&I6XQ,LS4F&3!I06>ZWXSFF)^YM.H`&@2@AMKV;$2XYV_<.F'`K&.T-9"
MM3DA9&VG\5M!WA*B(-T/5(M!@Q6_@QM9+(`V1E1CI*`H-3!MC0%22L#B`O"K
M:*X@DO0#'Y%48_^=%13$/%\BSFD.M\>%/--%',(9`L@PN3S-KVV_&Y'/Y`,?
M691A;;$1VM;B0ATRM%(_,W,%`A9`@(L.C@!0S!QQI%2`1@6'0F.XD)1.Q3%7
M?*9I!*E3#"?P,)%R)I@S665@ZD.95G9PBG`!$X5D(26[',D!$Z!-`LO3G@:X
MJ%90NMX5I;8>V(`4`(J11048$(!8&&:IKL'<V1IT&6-68`4$Z!9V_#$FOL2E
M7G"=QPL+-A*AFC$!?+L@'@^R``I437!0S9[@5N"`8*ZM`@Z(V<Q@F:FQLH!N
M9X6C8QI0!HLR)S`-*--S(MN`DU6@`2NX1VEA:I`"##1J-QH`4&7B5R'_N:(`
M#W20D`[B"M3Y]D>]=<@=3P.FM5&V6KPEE&P/XE5Q?6<`<<I);6=RW(5T9S?_
M\1I!3MC+B&"M3P\<4'ZN6,\+!?4BJJEN0M2[$:QU*$N\1*]XWB<0RG;%`@U(
M@+R$`Q&^4M*\$*NO1!Q'``<,9%=M<TUU^8H`%UF)O:F,R71OHEXN4:A-;YEM
MQR02GZEQY#;(-2^F_%N1K"RD#$UL40]Y.R@.EN$@)$9,7TVL$!:\$(#0-1B,
M(Q*PTA(DQJ.A\8XW5]JWR`+(RBH*B2?\E+K-(Q;1-1,L4C$+_O@#%J?D%`)@
MX9"'D62A`DD%`JZ<"HHPN2@G+(`!R$6&>JQB_Q6JF$5!Z"%GA<R"'A(#@``P
M,."!I"++!1##0N5A($\8P,Q"9HB?KBP/@1A@%5*<Y(4<!B/7X`8#&+"TI7]<
MD%7,`L2<4H5@#""`2#_DS"8N`*0!<&<`\$,><3;`I^D!YS+#0A6KH`<"4L%G
M`<":SPB`M:<'@H$W9P(MLU"%J/4,9V##NM3$\80J"-9L^/3C80((-B8^#>=#
MGSK1$BD`)@2PBGIP614".``9Y&$`<<_BT0B@AP#(8`X$(`+/JN#'`:8]BU60
M(=<#X<<J$-`/#+@BUI!&=RJF36H$K,+;`,C$H<-`CU3T@\L7$O2M$6"`1N\9
M%A<7\4)0G160SR(5>_^.>)GU;(!70-KA#H>%/^8]BU*O@LL5Y\>A24WLG6.@
MWQ>Z=B;*+(":9P(#!1\(/60^;9839^`(4`6K2XWN!:ABY0TA.5;6'1BI#SOB
M57[YP%71''F0`>4`6$69S8YI`&``VF[GLP'XD0I(NT+0PQ9`*NB!@0+`0C#R
M*+/:`<#NK@>=XU0W0"K^_FUP0R05VWXTU>O\<#)(_=;,-D"]$='HJZO\U@;(
M]T!2_G:'8X`?5*='Z#F^"D1@@#H"R`2SDWT;51A@XP8(@YX#SV=>9]WQ_:7U
M*K(-``-T1O$(P(`__,%G`/#]V&IV^UC:77QZR*/YK$8$JP\-BU7(`RVK",.F
MPP52;%W#Q^QZCC-![IQ\`*3BT`@@M\%K_GO@YWDB!(OZ?@,SEJ/?:O`,P26Y
MA13V5Q+)I@K8%RBKT`\#YQ#RH'V+4H`D,3`+008REV1])EQ-(8%?)A0QUBE:
MQX$E,8#2)8(F6!(A>((J*!4KV(($Z((PB&@Q.(,0D8(T*($V>(/VEX,ZZ'C_
A\(-`&(1".(1$6(1&>(1(F(1*N(1,V(1.^(10&(0!`0`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
